ClearPoint Neuro (ClearPoint Neuro) Total Inventories : $7.96 Mil (As of Mar. 2024)

View and export this data going back to 2012. Start your Free Trial

What is ClearPoint Neuro Total Inventories?

ClearPoint Neuro's total inventories for the quarter that ended in Mar. 2024 was $7.96 Mil. ClearPoint Neuro's average total inventories from the quarter that ended in Dec. 2023 to the quarter that ended in Mar. 2024 was $7.94 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. ClearPoint Neuro's Net-Net Working Capital per share for the quarter that ended in Mar. 2024 was $0.81.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. ClearPoint Neuro's Days Inventory for the three months ended in Mar. 2024 was 232.54.

Inventory Turnover measures how fast the company turns over its inventory within a year. ClearPoint Neuro's Inventory Turnover for the quarter that ended in Mar. 2024 was 0.39.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. ClearPoint Neuro's Inventory-to-Revenue for the quarter that ended in Mar. 2024 was 1.04.

ClearPoint Neuro Total Inventories Historical Data

The historical data trend for ClearPoint Neuro's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ClearPoint Neuro Total Inventories Chart

ClearPoint Neuro Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Inventories

Get a 7-Day Free Trial

3.24

4.94

9.30

7.91

ClearPoint Neuro Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Inventories	Get a 7-Day Free Trial															9.81	9.20	8.99	7.91	7.96

ClearPoint Neuro Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

ClearPoint Neuro (NAS:CLPT) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

ClearPoint Neuro's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2024 is

	Net-Net Working Capital Per Share (Q: Mar. 2024 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(35.353	+	0.75 * 2.511	+	0.5 * 7.96	-	19.053
-	0	-	0)	/	27.4163
=	0.81

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

ClearPoint Neuro's Days Inventory for the three months ended in Mar. 2024 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Mar. 2024 )	/	Cost of Goods Sold (Q: Mar. 2024 )	*	Days in Period
	=	7.9355	/	3.114	*	365 / 4
	=	232.54

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

ClearPoint Neuro's Inventory Turnover for the quarter that ended in Mar. 2024 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Mar. 2024 )	/	Average Total Inventories (Q: Mar. 2024 )
	=	3.114	/	7.9355
	=	0.39

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

ClearPoint Neuro's Inventory to Revenue for the quarter that ended in Mar. 2024 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	7.9355	/	7.639
	=	1.04

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

ClearPoint Neuro Total Inventories Related Terms

Thank you for viewing the detailed overview of ClearPoint Neuro's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

ClearPoint Neuro (ClearPoint Neuro) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ClearPoint Neuro Inc (NAS:CLPT) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

N/A

Address

120 S. Sierra Avenue, Suite 100, Solana Beach, CA, USA, 92075

Website

https://www.clearpointneuro.com

ClearPoint Neuro Inc is a medical device company based in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain and heart under direct, intra-procedural magnetic resonance imaging (MRI) guidance. The company's ClearPoint system, which is in commercial use in the United States, is used to perform minimally invasive surgical procedures in the brain and ClearTrace is used to perform minimally invasive surgical procedures in the heart. The company's products and product candidates include ClearPoint neuro system, MRI-guided drug delivery, and Thermal therapy system.

Executives

Lynnette C Fallon	director	108 CHERRY HILL DRIVE, BEVERLY MA 01915
Linda M. Liau	director	120 S. SIERRA AVENUE, SUITE 100, SOLANA BEACH CA 92075
Mazin Sabra	officer: Chief Operating Officer	120 S. SIERRA AVENUE, SUITE 100, SOLANA BEACH CA 92075
Joseph Michael Burnett	director, officer: CEO and President	C/O MRI INTERVENTIONS, INC., 5 MUSICK, IRVINE CA 92618
L. Jeremy Stigall	officer: GM, Biologics & Drug Delivery	120 S. SIERRA AVENUE, SUITE 100, SOLANA BEACH CA 92075
Danilo D'alessandro	officer: Vice President, Finance	5 MUSICK, IRVINE CA 92618
Harold A Hurwitz	officer: Chief Financial Officer
R John Fletcher	director	C/O VYANT BIO, INC., 201 ROUTE 17 NORTH, 2ND FLOOR, RUTHERFORD NJ 07070
Girin Pascal E R	director	C/O MRI INTERVENTIONS, INC., 5 MUSICK, IRVINE CA 92618
B Kristine Johnson	director	366 FERNDALE RD S, WAYZATA MN 55391
Timothy T. Richards	director	ONE COMMERCE SQUARE, SUITE 2550, MEMPHIS TN 38103
Matthew B. Klein	director	C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Marcio Souza	director	C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Voyager Therapeutics, Inc.	10 percent owner	75 HAYDEN AVENUE, LEXINGTON MA 02421
Wendelin C Maners	officer: Vice President, Marketing	ONE COMMERCE SQUARE, SUITE 2550, MEMPHIS TN 38103